What is Qoolabs?
Qoolabs Inc. is a prominent provider of rabbit monoclonal antibody services, focusing on the creation of high-quality antibodies essential for research, diagnostics, and therapeutic advancements. Leveraging its proprietary QMAb technology, the company excels in the rapid generation of highly specific and sensitive antibodies capable of targeting a diverse array of entities, including small molecules, proteins, and complex mixtures. Qoolabs serves a clientele within the scientific and medical research communities, offering bespoke solutions designed to streamline the antibody development process and accelerate R&D projects through innovative antibody solutions.
How much funding has Qoolabs raised?
Qoolabs has raised a total of $66K across 1 funding round:
Debt
$66K
Debt (2021): $66K with participation from PPP
Key Investors in Qoolabs
PPP
Public-Private Partnership
What's next for Qoolabs?
With the recent influx of substantial expansion capital, Qoolabs is strategically positioned for significant growth and operational scaling. This funding is expected to bolster its research and development capabilities, potentially leading to the expansion of its QMAb technology applications and the broadening of its service offerings. The company's focus on advancing research and development projects through innovative antibody solutions, coupled with its established position in the market, suggests a future trajectory aimed at solidifying its leadership in the antibody services industry and exploring new therapeutic and diagnostic frontiers.
See full Qoolabs company page
